Sphere Bio’s Post

🔍 The future of cell line development is here! Discover how we're contributing to advancements in biotherapeutics with a featured article on IPT Online, written by Maryam Ahmadi. "Advancing Cell Line Development: How Next-Gen Innovation Meets Industry Challenges" explores the revolutionary capabilities of platforms like Cyto-Mine® in overcoming challenges and accelerating research. 📖 Read the article now: https://bit.ly/3ZvhOa5 #SphereFluidics #CellLineDevelopment

Heading to #BioIT2024? Catch my session on April 16, 4:00-4:15 PM. I'll be discussing "Bridging Data and Discovery: Leveraging High-Quality, High-Volume Biomedical Datasets". Expect some examples and insights on making the process faster and more cost-effective. Also, check out our April 15 session, 2:20-2:50 PM, on "Accelerating Drug Discovery with Comprehensive Curated Knowledge". We'll showcase how knowledge graphs in Neo4j can unlock new potentials in drug discovery. If you're at the conference, I'd love to connect! Let’s discuss innovations in biotech or dive into the specifics of these technologies. #BioITWorld #DrugDiscovery #MachineLearning

Check out our new infographic with Technology Networks: https://lnkd.in/gQ67HFNR High-throughput screening is a key strategy in drug discovery, allowing rapid automated testing of large libraries of compounds to assess their effects. This infographic presents recent key innovations that ensure reliable, high-throughput, automated flow cytometry workflows. #FlowCytometry #HighThroughputScreening #DrugDiscovery #LabAutomation #LifeScience

Check out our new infographic with Technology Networks: https://lnkd.in/gQ67HFNR High-throughput screening is a key strategy in drug discovery, allowing rapid automated testing of large libraries of compounds to assess their effects. This infographic presents recent key innovations that ensure reliable, high-throughput, automated flow cytometry workflows. #FlowCytometry #HighThroughputScreening #DrugDiscovery #LabAutomation #LifeScience

Check out our new infographic with Technology Networks: https://lnkd.in/gQ67HFNR High-throughput screening is a key strategy in drug discovery, allowing rapid automated testing of large libraries of compounds to assess their effects. This infographic presents recent key innovations that ensure reliable, high-throughput, automated flow cytometry workflows. #FlowCytometry #HighThroughputScreening #DrugDiscovery #LabAutomation #LifeScience

🚨 miDiagnostics Secures €30M Series D Funding to Advance Sterility Testing for Biopharma! 🧬💡 Belgium-based MiDiagnostics has raised €30M in its Series D funding round, led by Thermo Fisher Scientific and supported by existing investors like Alychlo, VMF Invest, and Pamica. With this new funding, MiDiagnostics will: 🔬 Accelerate development of a revolutionary sterility test for batch release in biopharma using its cutting-edge qPCR technology. 🌍 Leverage Thermo Fisher’s expertise to bring innovative solutions to market. 💻 MiDiagnostics’ tech combines: ✔️ A nanofluidic processor on a silicon chip ✔️ A compact reader for rapid analyte measurement MiDiagnostics CEO Katleen Verleysen stated: "This funding will enable us to expedite our development efforts and revolutionize sterility testing in the biopharma sector.” Notably, MiDiagnostics is also behind a SARS-CoV-2 breath test developed in 2021, showcasing its commitment to pushing boundaries in diagnostics. 🔗 Collaborations with imec and The Johns Hopkins University highlight the firm’s strong foundation in innovation. #Diagnostics #Biopharma #FundingNews #Innovation #ThermoFisher #LifeSciences #MiDiagnostics #PCRTechnology

As flow cytometry evolves with technological advancements, biomarker teams face new challenges in standardization and interpretation. How can we ensure robust insights across programs? Check out our new Spotlight with KCAS Bio to learn more about this! >>> https://hubs.ly/Q02shnWV0

What major trends are informing and accelerating development of novel molecular entities (NMEs)? Sapient's Dr. Jonathan Usuka addresses this question, explaining how new drug modalities are expanding the #druggable space and how next-gen #proteomics methods are enabling rapid exploration of the broader proteome for novel target identification. Listen below and access the full #webinar to see why this confluence of innovation is ushering in a new golden era for #targetID: https://lnkd.in/eNgUxKaM

At Doloromics, we believe the future of therapeutics lies in asking bold questions and embracing technology that pushes the boundaries of what’s possible. One way we do this is by working with groups like CytoTronics to capture the intricate dance of neurons growing across semiconductor-based platforms. Doloromic's Principal Scientist, Dale George, is pioneering these techniques to harness electrochemical and electrophysiological signals as a means of better informing therapeutic drug discovery. Check out her recent work below, and watch as our 3D PNS models grow across electrode plates.

Rare cells